This study helps in understanding baseline lipid parameters in the second and third trimester among pregnant women in India. Total Cholesterol, Triglycerides, LDL-Cholesterol, VLDL-Cholesterol increased in both second and third trimester. The increase is more in third trimester, when compared to second. HDL-Cholesterol is decreased in third trimester when compared to second trimester.
doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Introduction
Hyponatremia is a common electrolyte abnormality that has been associated with poor outcomes in several conditions including acute myocardial infarction (AMI). However, those studies were performed in the era before percutaneous coronary intervention (PCI), focused mostly on ST-elevation myocardial infarction (STEMI), and sodium levels up to 72 h of admission. The purpose of this study was to identify the association between hyponatremia and clinical outcomes in patients with acute myocardial infarction.
Methods
We performed a retrospective analysis of patients with a diagnosis of non-ST-elevation myocardial infarction (NSTEMI) and STEMI presenting at our institution from March 2021 to September 2021. Our independent variables were sodium levels on the day of admission and up to 7 days later. Dependent variables were in-hospital mortality, 30-day mortality, length of hospital stay, intensive care admission, new heart failure diagnosis, and ejection fraction.
Results
50.2% of patients had hyponatremia up to 7 days of admission. Intensive care admission was higher in patients with hyponatremia up to7 days (69.7% vs 54.3%, P 0.019, OR 1.9), they had worse 30-day mortality (12.7% vs to 2.2%, P 0.004, OR 6.5), in hospital mortality (9.9% vs 1.1%, P 0.006, OR 9.9), and new heart failure diagnosis (31.5% vs 17.9%, P < 0.043, OR 2.1). Hyponatremia on admission was associated with in-hopital mortality (16.3% vs 3.8%, P 0.004, OR 4.9), 30-day mortality (18.4% vs 5.9%, P 0.017, OR 3.5).
Conclusions
This study suggests that hyponatremia on admission and at any point during the first seven days of hospitalization are associated with in-hospital and 30-day mortality.
Background: Dengue fever with its severe manifestations, such as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) has emerged as a major public health problem of international concern. Dengue, presenting as dengue fever (DF) or DHF or DSS, also has some effect on liver function. This study was conducted to find out the impact of dengue on liver function and correlation between clinical manifestation of dengue fever and degree of liver injury.
Materials and methods:This prospective randomized study was done on 200 outpatient department/inpatient department (OPD/IPD) patients in age group of 12 to 60 years including both sexes who confirm to the predetermined inclusion and exclusion criteria. Investigation included measure ments of serum glutamic oxaloacetic transaminase (SGOT), serum glu tamic pyruvic transaminase (SGPT), prothrombin time/inter national normalized ratio (PT/INR) and creatinine. Degree of liver involve ment was classified in four groups.Results: Out of 200 cases, 181 (90.5%) were diagnosed as dengue fever, nine (4.5%) as DHF, five (2.5%) as DSS, five (2.5%) as hepatorenal involvement; 24 (12.0%) had grade 0 liver injury, 126 (63.0%) had grade 1 liver injury, 34 (17%) had grade 2 liver injury, 10 (5.0%) had grade 3 liver injury and six (3.0%) had grade 4 liver injury.Conclusion: Mild elevation of the liver enzymes is a common feature of dengue infection. There is high relation between the degree of liver damage and the appearance of the complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.